(Q38608260)

4 September 2017

title

Targeting key proximal drivers of type 2 inflammation in disease (English)

1 reference

4 September 2017

0 references

Namita A Gandhi

1

1 reference

4 September 2017

Brandy L Bennett

2

1 reference

4 September 2017

Neil M H Graham

3

1 reference

4 September 2017

Gianluca Pirozzi

4

1 reference

4 September 2017

Neil Stahl

5

1 reference

4 September 2017

George D Yancopoulos

6

1 reference

4 September 2017

publication date

16 October 2015

1 reference

Nature Reviews Drug Discovery

4 September 2017

published in

1 reference

4 September 2017

volume

15

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

35-50

1 reference

Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys

4 September 2017

cites work

1 reference

A global survey of changing patterns of food allergy burden in children

21 January 2018

1 reference

Allergy and allergic diseases. Second of two parts

21 January 2018

1 reference

Allergy and allergic diseases. First of two parts

21 January 2018

1 reference

Type 2 cytokines: mechanisms and therapeutic strategies

21 January 2018

1 reference

At the bedside: the emergence of group 2 innate lymphoid cells in human disease

21 January 2018

1 reference

Molecular interactions between glucocorticoids and long-acting beta2-agonists.

21 January 2018

1 reference

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

21 January 2018

1 reference

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

21 January 2018

1 reference

Omalizumab for the treatment of chronic urticaria

21 January 2018

1 reference

Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR.

21 January 2018

1 reference

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.

21 January 2018

1 reference

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

21 January 2018

1 reference

Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis

21 January 2018

1 reference

Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.

21 January 2018

1 reference

Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities

21 January 2018

1 reference

Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity

21 January 2018

1 reference

Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.

21 January 2018

1 reference

The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4

21 January 2018

1 reference

Inflammation in chronic rhinosinusitis and nasal polyposis

21 January 2018

1 reference

Differentiation of chronic sinus diseases by measurement of inflammatory mediators.

21 January 2018

1 reference

Pathogenesis of chronic rhinosinusitis.

21 January 2018

1 reference

State of the art treatment of nasal polyposis.

21 January 2018

1 reference

An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice.

21 January 2018

1 reference

Disruption of the murine IL-4 gene blocks Th2 cytokine responses.

21 January 2018

1 reference

Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses

21 January 2018

1 reference

Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter

21 January 2018

1 reference

IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites

21 January 2018

1 reference

STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts

21 January 2018

1 reference

IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance

21 January 2018

1 reference

Interleukin 4 inhibits the interleukin 2-induced production of its functional antagonist, interferon gamma

21 January 2018

1 reference

Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease.

21 January 2018

1 reference

IL-13 receptors and signaling pathways: An evolving web

21 January 2018

1 reference

Localization of human interleukin 13 receptor in non-haematopoietic cells.

21 January 2018

1 reference

Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses

21 January 2018

1 reference

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

21 January 2018

1 reference

Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells.

21 January 2018

1 reference

Interleukin-4 receptor signaling pathways in asthma pathogenesis

21 January 2018

1 reference

Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.

21 January 2018

1 reference

Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody

21 January 2018

1 reference

Impaired development of Th2 cells in IL-13-deficient mice.

21 January 2018

1 reference

Regulation of interleukin-13 receptor constituents on mature human B lymphocytes

21 January 2018

1 reference

IL-5- and eosinophil-mediated inflammation: from discovery to therapy

21 January 2018

1 reference

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

21 January 2018

1 reference

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma

21 January 2018

1 reference

Allergy, asthma, and inflammation: which inflammatory cell type is more important?

21 January 2018

1 reference

Eosinophil trafficking in allergy and asthma.

21 January 2018

1 reference

Attenuation of allergic airway inflammation in IL-4 deficient mice.

21 January 2018

1 reference

Mechanisms of airway hyperresponsiveness

21 January 2018

1 reference

Requirement for IL-13 independently of IL-4 in experimental asthma

21 January 2018

1 reference

Interleukin-13: central mediator of allergic asthma

21 January 2018

1 reference

Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma

21 January 2018

1 reference

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

21 January 2018

1 reference

IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells

21 January 2018

1 reference

IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4.

21 January 2018

1 reference

Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma

21 January 2018

1 reference

Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling

21 January 2018

1 reference

Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity

21 January 2018

1 reference

Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis.

21 January 2018

1 reference

Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions

21 January 2018

1 reference

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

Cytokine-directed therapies for the treatment of chronic airway diseases

21 January 2018

1 reference

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

21 January 2018

1 reference

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

21 January 2018

1 reference

Targeting interleukin-4 in asthma: lost in translation?

21 January 2018

1 reference

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

21 January 2018

1 reference

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor

21 January 2018

1 reference

Asthma: defining of the persistent adult phenotypes

21 January 2018

1 reference

Cluster analysis and clinical asthma phenotypes.

21 January 2018

1 reference

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

21 January 2018

1 reference

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies

21 January 2018

1 reference

Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

21 January 2018

1 reference

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

Mepolizumab treatment in patients with severe eosinophilic asthma

21 January 2018

1 reference

Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab

21 January 2018

1 reference

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

21 January 2018

1 reference

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

21 January 2018

1 reference

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

Advances in management of atopic dermatitis: new therapies and novel uses of existing treatments

21 January 2018

1 reference

Emerging drugs for atopic dermatitis

21 January 2018

1 reference

Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta

21 January 2018

1 reference

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

21 January 2018

1 reference

Oral steroids and doxycycline: two different approaches to treat nasal polyps.

21 January 2018

1 reference

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.

21 January 2018

1 reference

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis

21 January 2018

1 reference

Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis

21 January 2018

1 reference

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis.

21 January 2018

1 reference

Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme.

21 January 2018

1 reference

Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids.

21 January 2018

1 reference

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group.

21 January 2018

1 reference

Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance

21 January 2018

1 reference

Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

21 January 2018

1 reference

Development and validation of a questionnaire to measure asthma control.

21 January 2018

1 reference

Methods used in clinical development of novel anti-asthma therapies

21 January 2018

1 reference

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.

21 January 2018

1 reference

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study

21 January 2018

1 reference

21 January 2018

1 reference

Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial

31 March 2020

1 reference

Minimizing complications from systemic glucocorticosteroid use.

31 March 2020

1 reference

Infliximab in the treatment of moderate to severe atopic dermatitis

31 March 2020

1 reference

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

31 March 2020

1 reference

Immunological differences between intrinsic and extrinsic types of atopic dermatitis

31 March 2020

1 reference

Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness

31 March 2020

1 reference

Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients

31 March 2020

1 reference

Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis

31 March 2020

1 reference

Rhinosinusitis: establishing definitions for clinical research and patient care

31 March 2020

1 reference

IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells

31 March 2020

1 reference

Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity

31 March 2020

1 reference

Critical role for IL-13 in the development of allergen-induced airway hyperreactivity

31 March 2020

1 reference

Bronchoprovocation testing in asthma

31 March 2020

1 reference

Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease

31 March 2020

1 reference

Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells

31 March 2020

1 reference

No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients

31 March 2020

1 reference

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

31 March 2020

1 reference

Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma

31 March 2020

1 reference

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

31 March 2020

1 reference

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

31 March 2020

1 reference

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

31 March 2020

1 reference

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

31 March 2020

1 reference

EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis

31 March 2020

1 reference

Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus

31 March 2020

1 reference

Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics

31 March 2020

1 reference

12 December 2020

Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice

1 reference

12 December 2020

Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling

1 reference

12 December 2020

IL-4 directs the development of Th2-like helper effectors

1 reference

12 December 2020

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study

1 reference

12 December 2020

IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy.

1 reference

12 December 2020

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group

1 reference

12 December 2020

An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo

1 reference

12 December 2020

Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids

1 reference

12 December 2020

Side-effects of corticosteroid agents

1 reference

12 December 2020

Omalizumab for chronic urticaria

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4624

1 reference

Dimensions Publication ID

4 September 2017

1006737496

0 references

1 reference